BackENDRA Life Sciences- Warrants (12/05/2022) Overview

ENDRA Life Sciences- Warrants (12/05/2022) Current Assets

Latest current assets for NDRAW: $5.6M.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$5.59M
201.53% YoYΔ $3.73M vs prior year quarter

Peer trimmed avg / median

Loading

ENDRA Life Sciences- Warrants (12/05/2022) Current Assets History

Loading

ENDRA Life Sciences- Warrants (12/05/2022) vs. peers: Current Assets Comparison

Loading

ENDRA Life Sciences- Warrants (12/05/2022) Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

ENDRA Life Sciences- Warrants (12/05/2022) (NDRAW) FAQ

As of the most recent data (June 2026), NDRAW shows a current assets of $5.6M. That compares with $1.9M in the prior-year period — up 201.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NDRAW's current assets is now $5.6M (was $1.9M) — a 201.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether ENDRA Life Sciences- Warrants (12/05/2022) is outperforming or lagging.

Tracking NDRAW's current assets over time shows whether ENDRA Life Sciences- Warrants (12/05/2022) is scaling, shrinking, or reshaping that part of the business. The current reading is $5.6M That compares with $1.9M in the prior-year period — up 201.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current assets page, Stockcircle has ENDRA Life Sciences- Warrants (12/05/2022)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current assets (currently $5.6M) with ownership activity and broader fundamentals.

ENDRA Life Sciences- Warrants (12/05/2022)'s current assets is $5.6M; compare it with other Technology names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.